⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19085497 | 0.77 | — | — | |
| SCHEMBL21413937 | 0.62 | CHRM2 (0.49) | — | |
| SCHEMBL18427298 | 0.62 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL12803075 | 0.61 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL27800482 | 0.61 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL25054047 | 0.61 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL13077728 | 0.61 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL24065677 | 0.60 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL21677362 | 0.60 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL20468593 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |